Li J, Shi C, Chen J, Zhao Y, Du J, Song J
J Hepatocell Carcinoma. 2025; 12:289-299.
PMID: 39991513
PMC: 11844194.
DOI: 10.2147/JHC.S494668.
Chen S, Qi H, Tan H, Cao F, Xie L, Huang T
J Hepatocell Carcinoma. 2025; 12:205-218.
PMID: 39925626
PMC: 11804238.
DOI: 10.2147/JHC.S505979.
Xue Z, Yao M, Chen K, Huang T, Li J, Chen J
Sci Rep. 2025; 15(1):4188.
PMID: 39905151
PMC: 11794854.
DOI: 10.1038/s41598-025-88813-8.
Xie G, Zhong Z, Ye T, Xiao Z
BMC Surg. 2025; 25(1):47.
PMID: 39875933
PMC: 11776151.
DOI: 10.1186/s12893-025-02778-z.
An C, Wu S, Zuo M, Li W, Li K, Wu P
Ther Adv Med Oncol. 2025; 17:17588359241306648.
PMID: 39759827
PMC: 11694308.
DOI: 10.1177/17588359241306648.
Update on Resection Strategies for Hepatocellular Carcinoma: A Narrative Review.
Lee J, Choi H, Kim J, Lee T, Yoon Y
Cancers (Basel). 2024; 16(23).
PMID: 39682279
PMC: 11640626.
DOI: 10.3390/cancers16234093.
The current status and future of targeted-immune combination for hepatocellular carcinoma.
Hao L, Li S, Ye F, Wang H, Zhong Y, Zhang X
Front Immunol. 2024; 15:1418965.
PMID: 39161764
PMC: 11330771.
DOI: 10.3389/fimmu.2024.1418965.
Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy.
Qian Z, Xiong W, Mao X, Li J
Biomolecules. 2024; 14(6).
PMID: 38927103
PMC: 11202214.
DOI: 10.3390/biom14060700.
Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations.
Berning P, Schroer A, Adhikari R, Razavi A, Cornelis F, Erinjeri J
Front Oncol. 2024; 14:1324095.
PMID: 38406802
PMC: 10884243.
DOI: 10.3389/fonc.2024.1324095.
Clinical application of spectral CT perfusion scanning in evaluating the blood supply source of portal vein tumor thrombus in hepatocellular carcinoma.
Pan C, Dai F, Sheng L, Li K, Qiao W, Kang Z
Front Oncol. 2024; 13:1348679.
PMID: 38304029
PMC: 10832025.
DOI: 10.3389/fonc.2023.1348679.
Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis.
Li Z, Xu Y, Qu W, Liu P, Zhu Y, Li H
Oncol Lett. 2023; 26(6):534.
PMID: 38020293
PMC: 10655037.
DOI: 10.3892/ol.2023.14121.
Laparoscopic open radical resection in management of gallbladder carcinoma: A systematic review and meta-analysis.
He S, Yu T, Cao J, Zhou X, Chen Z, Jiang W
World J Clin Cases. 2023; 11(27):6455-6475.
PMID: 37900219
PMC: 10601008.
DOI: 10.12998/wjcc.v11.i27.6455.
M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma.
Yang L, Han P, Cui T, Miao Y, Zhao T, Cui Z
Front Immunol. 2023; 14:1251648.
PMID: 37809069
PMC: 10556255.
DOI: 10.3389/fimmu.2023.1251648.
Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z, Wang Y, Wu B, Liu Y, Wang Y, Ren Z
Front Immunol. 2023; 14:1235724.
PMID: 37720223
PMC: 10502306.
DOI: 10.3389/fimmu.2023.1235724.
A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.
Huang J, Liang R, Lu C, Lu L, Li S, Tang M
Int J Mol Sci. 2023; 24(17).
PMID: 37686291
PMC: 10487462.
DOI: 10.3390/ijms241713486.
Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma.
Zhang R, Zhou H, Lu H, Yu H, Tang W, Qiu M
Radiat Oncol. 2023; 18(1):129.
PMID: 37542246
PMC: 10403970.
DOI: 10.1186/s13014-023-02309-1.
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective....
Chen S, Shi F, Wu Z, Wang L, Cai H, Ma P
J Hepatocell Carcinoma. 2023; 10:1209-1222.
PMID: 37533600
PMC: 10390715.
DOI: 10.2147/JHC.S417550.
Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
Chen J, Lai L, Zhou C, Luo J, Wang H, Li M
Cancer Imaging. 2023; 23(1):70.
PMID: 37481660
PMC: 10362718.
DOI: 10.1186/s40644-023-00581-8.
Contrast-enhanced ultrasound guidance improves the therapeutic efficacy of radiofrequency ablation in liver cancer patients.
Sun Q, Wang A, Chang H
Am J Transl Res. 2023; 15(6):3856-3863.
PMID: 37434841
PMC: 10331678.
Clinical presentation and management modalities of gallbladder cancer in Sudan: A single-center study.
Adam K, Abdelrahim E, Doush W, Abdelaziz M
JGH Open. 2023; 7(5):365-371.
PMID: 37265936
PMC: 10230110.
DOI: 10.1002/jgh3.12906.
